# Phase I Study of LB-100 With Docetaxel in Solid Tumors

> **NCT01837667** · PHASE1 · COMPLETED · sponsor: **Lixte Biotechnology Holdings, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Tumors
- Neoplasms
- Cancer

## Interventions

- **DRUG:** LB-100 for Injection
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01837667
- **Lead sponsor:** Lixte Biotechnology Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01837667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01837667, "Phase I Study of LB-100 With Docetaxel in Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01837667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*